Sugi Predict

Sugi Predict / Compounds / SCHEMBL9744176

SCHEMBL9744176

SCHEMBL9744176

Nc1ccc(-c2cn3c(n2)SCC3)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.72
▸ NPC1 O15118 7/20 0.72
▸ RAB9A P51151 7/20 0.72
▸ MEN1 O00255 7/20 0.72
▸ KMT2A Q03164 7/20 0.72
▸ SMN1; SMN2 Q16637 5/20 0.72
▸ GAA P10253 2/20 0.72
▸ GFER P55789 1/20 0.72
▸ TP53 P04637 1/20 0.71
▸ GLA P06280 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ LMNA P02545 1/20 0.67
▸ NFKB1 P19838 1/20 0.67
▸ NFKB2 Q00653 1/20 0.67
▸ RELA Q04206 1/20 0.67
▸ ALDH1A1 P00352 4/20 0.62
▸ KDM4E B2RXH2 2/20 0.62
▸ NSD2 O96028 1/20 0.62
▸ ALPL P05186 1/20 0.62
▸ POLB P06746 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9744862 0.84 MAPT (1.00) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL9742712 0.84 MAPT (0.72) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3202839 0.81 MAPT (0.71) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL9738237 0.80 MAPT (0.67) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4424341 0.77 KMT2A (0.70) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL13856561 0.77 MAPT (1.00) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL10562991 0.75 MEN1 (1.00) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL8086759 0.75 NPC1 (0.60) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL8091839 0.74 NPC1 (0.59) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL18281439 0.72 MAPT (0.59) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-2681221-B1 TRICYCLIC INHIBITORS OF KINASES ABBVIE INC (US) 2016-05-18 — — EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2681221-A1 TRICYCLIC INHIBITORS OF KINASES AbbVie Inc. (US) 2014-01-08 — — EP disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
WO-2012161812-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-11-29 — — WO disclosed
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-08-30 — — US disclosed
EP-0203787-B1 Process for preparing pyridyl-substituted imidazo[2,1-b]thiazoles and thiazines SMITHKLINE BEECHAM CORPORATION (US) 1992-12-30 — — EP disclosed
US-5008390-A Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and corresponding thiazines SMITHKLINE BECKMAN CORPORATION (US) 1991-04-16 — — US disclosed
US-4803279-A 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines. SMITHKLINE BECKMAN CORPORATION (US) 1989-02-07 — — US disclosed
EP-0203787-A2 Process for preparing pyridyl-substituted imidazo[2,1-b]thiazoles and thiazines SMITHKLINE BEECHAM CORPORATION (US) 1986-12-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 501/4885NPC1 4727/4885RAB9A 944/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 470/4885NPC1 4398/4885RAB9A 872/4885
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES WEE1, WEE2, CDK1 MAPT 2484/4885NPC1 3019/4885RAB9A 2519/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK MAPT 470/4885NPC1 4398/4885RAB9A 872/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 MAPT 634/4885NPC1 4130/4885RAB9A 621/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885NPC1 4434/4885RAB9A 860/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885NPC1 4434/4885RAB9A 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.